Home / The Company / News

Annoroad Gene Technology


1541751998575394.jpg 1541752064979173.jpg


Annoroad Gene Technology, founded in 2012 with headquarters in Beijing, is a well-known enterprise in China’s genomics industry, a leading NIPT service provider in China, and a best-in-class medical genomics center in Asia, which specializes in the application of next-generation genomics in human health and life science research.


Since its founding, Annoroad has been recognized with a series of prestigious designations including national high-tech enterprise, one of the pilot organizations approved by the NHFPC (National Health and Family Planning Commission) to take part in the high-throughput sequencing clinical application, one of the first gene detection technology demonstration centers approved by the NDRC (National Development and Reform Commission), one of the Beijing Engineering Laboratory of Precision Medicine and Genetic Engineering approved by Beijing Municipal Development and Reform Commission, one of the enterprises included in the Beijing Biopharmaceutical Industry Leap-forward Development Program (G20 Program), Beijing ScientiÞ c and Technological R&D Institution. It has a post-doctoral scientiÞ c research station and is included in Top 30 Leading Technology Companies in China, and Top 50 Most Investment-Worthy Enterprises in China. 


Based on its core overseas and domestic talent teams, Annoroad has developed leading proprietary genome sequencing and bioinformatics technologies and established advanced high-throughput sequencing and high-performance computing platforms. Annoroad has launched NextSeq 550AR (CFDA No.:20173400330), a leading high-throughput benchtop sequencer, and SolarGenomics, a cloud-based genomic big data platform. Currently, Annoroad has put in place a comprehensive product system covering sequencing instrument and reagents, medical testing and research, scientific research service, Genomic big data service with a high reputation and built a strong presence along the upstream, midstream and downstream of the entire industry chain and powerful Bio-IT industrial service capabilities, which have been highly recognized by a wide range of partners.


As an endeavor to promote the development of human medical health, Annoroad has constructed a prominent multinational team of genomic experts,medical specialists, along with talents from relative fields. Furthermore, a comprehensive and sensible service system has been set up, with well-established brand effects. This system mainly serves within the scopes of individualized cancer therapy, monogenic inheritance testing, genetic examination, and reproduction healthcare. Annoroad has launched a number of outstanding clinical application of high-throughput sequencing project, including Non-invasive Prenatal Testing (NIPT) , Multi-gene Testing for Hematonosis, ctDNA Testing, Breast / Ovarian Cancer Gene Testing, etc. And also, Annoroad won the highly recognized by the majority partner in precision medical field.


As a hi-tech enterprise, Annoroad offers excellent sequencing and bioinformatic analysis service to meet the demands of life scientific research. Annogene, a sub-brand of Annoroad, has gone into partnership with prestige institutions around the globe, and also has devoted itself into providing collaborators with cutting-edge solutions and support to maximize their scientific success.


About Annoroad  South Center


1541752109175590.jpg 1541752113673247.jpg


Zhejiang Annoroad Biotechnology Co., Ltd. was officially completed in July 2018. As the South Center of Annoroad, it will rely on the core advantages of Annoroad Beijing headquarters in the genetic sequencing industry chain, middle and downstream resources, to build a medical inspection center, genetic research institute, instrument reagent manufacturing center, genetic health center. The four core functional genetic technology ecosystems strive to become a new business card for Yiwu. Together with the headquarters of Annoroad, we adhere to the concept of “enhancing the quality of life with technology and innovation” and jointly build medical and health care that integrates “big science, big manufacturing, big health, big service, big data and big resources”. An excellent company in the field.


After the completion of the Medical Testing Center, it will become one of the core testing bases in the field of reproductive health and cancer detection in the country, and the laboratory with the largest sample processing capacity in East China. The Gene Research Institute will have a world-class research team and become a leading international company. Sequencing Center and Large Data Processing Supercomputing Center, the world's only three-dimensional genomics research center, the world's leading single-cell multi-omics research center; Gene Health Center strives to become the most comprehensive genetic health industry in the nationwide detection technology and production platform Base, in the future will reach 150,000 years of test sample volume, thereby improving the level of residents' health management and disease prevention; in addition, the Gene Health Center will work with local medical regulatory authorities to promote standardized and industrialized genetic testing applications. The instrument reagent manufacturing center will form an upstream layout of the industrial chain and become a demonstration base for instrument and reagent manufacturing and operation management.


Annoroad South Center will rely on the unique location advantages, Guangzhou Annoroad and other subsidiaries in line with the North Center - Beijing headquarters, the formation of a "one South and a North double" nationwide Center, to build a leading eco-type enterprise in the genome industry, adhering to the concept of using technology and innovation to enhance the quality of life, to create a whole industry chain layout from upstream instruments, reagent manufacturing to midstream big data services and downstream medical, health and technology services applications. .


1541752129149635.jpg



Primary founder


Xia Zuoquan Chairman Angel Investor


Graduated from Beijing University of Science and Technology and Peking University Guanghua School of Management, Annoyouda Angel investor, BYD co-founder, current chairman of Annoyouda, chairman of Shenzhen Zhengxuan Investment, director of BYD, is a successful entrepreneur in China and One of the investors has extensive experience in corporate governance and risk control.


Li Dawei CEO Co-founder


Beijing Economic and Technological Development Zone “New Innovation Project · Qilin” talents, with nearly 20 years of research and development and management experience in the field of gene sequencing, is the first batch of domestic construction of sequencing platforms, new technology research and development, production and operation, financial management, supply chain system Build and manage comprehensive talents.


Chen Reconstruction President Co-Founder


Researcher, special expert in Beijing, visiting professor at Huazhong Agricultural University. Biotechnology and computer academic background, obtained double doctoral degrees from Paris 11 University and Sun Yat-sen University, completed postdoctoral research at the Curie Institute in France. He is currently the director of the Beijing Precision Medical and Genetic Engineering Laboratory and the vice chairman of the Chinese Research Hospitals Association for the Precision Diagnosis of Hematology. He has been rated as "Beijing Haiju Engineering Talents", "Zhongguancun Ten Seas to Start a New Star", "Beijing Economic and Technological Development Zone Leading Talents", "Beijing Economic and Technological Development Zone Overseas High-level Talents", the 8th Beijing Excellent Young talents, "2015-2016 Beijing Excellent Entrepreneur", 2017 "Capital Labor Medal", "Thirty-first Beijing Youth May Fourth Medal", "China Youth Entrepreneurship Award" winner, in Nature, Science More than 19 academic papers have been published in international journals such as Elife, Developmental Cell, Genome Biology, and Bioinformatics. (PubMed1 PubMed2)


Academic article published:


  Nature Structure & Molecular Biology. 2017 Jan 30. doi: 10.1038/nsmb.3365.


  Nature. 2016 July 18. doi: 10.1038.



Oncotarget. 2016 Jan 27. doi: 10.18632/oncotarget.7028


Scientific Repprt. 2015; 5: 16106. Published online 2015 November 4. doi: 10.1038/srep16106


eLIFE. 2016 Feb 2; 5. pii: e08851. doi: 10.7554/eLife.08851.


Genome Biol. 2015 Dec 1; 16:259. doi: 10.1186/s13059-015-0831-x.


PLoS Genet. 2015 May 14; 11(5):e1005247. doi: 10.1371/journal.pgen.1005247.


Dev Cell. 2014 Feb 24; 28(4):366-80. doi: 10.1016/j.devcel.2014.01.016.


Biochem Biophys Res Commun. 2014 Jan 31; 444(1):86-91. doi: 10.1016/j.bbrc.2014.01.018.


PLoS Genet. 2013 Nov; 9(11):e1003791. doi: 10.1371/journal.pgen.1003791.


Methods. 2013 Sep 1; 63(1): 76-84. doi: 10.1016/j.ymeth.2013.05.001.


Bioinformatics. 2012 Dec 1; 28(23): 3147-9. doi: 10.1093/bioinformatics/bts587.


Bioinformatics. 2012 Nov 1; 28(21): 2843-4. doi: 10.1093/bioinformatics/bts521.


RNA Biol. 2011 May-Jun; 8(3): 538-47.


RNA. 2011 Mar; 17(3): 390-400. doi: 10.1261/rna.2426511.


Genetics. 2008 May; 179(1): 21-30. doi: 10.1534/genetics.107.086025.


Science. 2007 Oct 12; 318(5848):245-50.


Genomics. 2007 Apr; 89(4): 490-501. Epub 2007 Jan 11.


Mol Biol Evol. 2009 Feb;26(2):327-34. doi: 10.1093/molbev/msn249. Epub 2008 Nov 4


Wang Hailiang Vice President Co-founder


Graduated from Shandong University Pharmacy (formerly Shandong Medical College), MBA of Guanghua School of Management. More than 20 years of experience in marketing management in the pharmaceutical industry. He has worked in drug marketing in Beijing Hospital and Merck East China. He used to be the vice president of the giant Hong Kong listed company.


share: